AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 8, 2021 at 10:22 AM.

  1. #1 cafead, Apr 8, 2021 at 10:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of adults with active psoriatic arthritis.

    article source
     
    Quote

Reply to Thread